Evaluation of Accelerator Mass Spectrometry in a Human Mass Balance and Pharmacokinetic Study–experience with C-labeled (r)-6-[amino(4- Chlorophenyl)(1-methyl-1h-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1- Methyl-2(1h)-quinolinone (r115777), a Farnesyl Transferase Inhibitor

Accelerator mass spectrometry (AMS) has been used in a human mass balance and metabolism study to analyze samples taken from four healthy male adult subjects administered nanoCurie doses of the farnesyl transferase inhibitor C-labeled (R)-6[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3chlorophenyl)-1-methyl-2(1H)-quinolinone ([C]R115777). Plasma, urine, and feces samples were collected at fixed timepoints after oral administration of 50 mg [C]R115777 (25.4 Bq/mg or 687 pCi/mg i.e., equivalent to 76.257 10 dpm) per subject. AMS analysis showed that drug-related C was present in the plasma samples with Cmax values ranging from 1.6055 to 2.9074 dpm/ml (1.0525–1.9047 g/ml) at tmax 2 to 3 h. The Cmax values for acetonitrile extracts of plasma samples ranged from 0.3724 to 0.7490 dpm/ml in the four male subjects. Drug-related C was eliminated from the body both in the urine and the feces, with a mean total recovery of 79.8 12.9% in the feces and 13.7 6.2% in the urine. The majority of drug-related radioactivity in urine and feces was excreted within the first 48 h. High-performance liquid chromatography (HPLC)-AMS profiles were generated from radioactive parent drug plus metabolites from pooled diluted urine, plasma, and methanolic feces extracts and matched to retention times of synthetic reference substances, postulated as metabolites. All HPLC separations used no more than 5 dpm injected on-column. The radioactive metabolite profiles obtained compared well with those obtained using liquid chromatography/tandem mass spectometry. This study demonstrates the use of AMS in a human phase I study in which the administered radioactive dose was at least 1000-fold lower than that used for conventional radio-